Activation of sickle red blood cell adhesion via integrin-associated protein/CD47–induced signal transduction by Brittain, Julia E. et al.
Introduction
Chronically impaired blood flow in sickle-cell disease
(SCD) leads to degenerative organ damage, whereas
acute vaso-occlusive crises in SCD patients can
progress to stroke, embolism, myocardial infarction,
and even death (1). Recent studies have demonstrated
that sickle red blood cells (SS RBCs), but not normal
RBCs, can bind to vascular endothelial cells (2, 3),
platelets (4), and the vascular adhesive proteins
thrombospondin (TSP) and laminin (5–9) in the
extracellular matrix. SS RBC adhesion to these vascu-
lar components is thought to promote, if not initiate,
vaso-occlusion (10, 11).
In the circulation, TSP is normally sequestered in
platelet α-granules. Upon activation, platelets release
TSP, causing plasma concentrations to increase by
three to four orders of magnitude (12). TSP also exists
as an integral component of the subendothelial matrix
(13, 14). In this immobilized form, TSP is a primary
adhesive substrate for endothelial cells (15) and may
become exposed to flowing blood as a result of the
extensive vascular damage present in SCD (16).
In SCD, both soluble and matrix TSP are proposed to
play a role in blood vessel occlusion by SS RBCs and
ensuing vaso-occlusive crises. We and others have
demonstrated that both purified and cell-secreted TSP,
when immobilized, is a primary adhesive substrate for
SS RBCs under relevant flow conditions (5, 17, 18, 19).
Soluble TSP, which is significantly elevated in the plas-
ma of SCD patients (20), may also serve as a linker mol-
ecule between SS RBCs and endothelial cells (7, 8).
On several hematopoietic cell types, integrin-associat-
ed protein (IAP; CD47) has been shown to function as
both a binding site for TSP as well as an agonist receptor
in response to soluble TSP. IAP, which binds to the cell-
binding domain of TSP (21), activates platelets (22),
mature T cells (23), and neutrophils (24). On platelets,
IAP increases platelet adhesion via a Gi-linked signal
transduction pathway (22, 25). IAP is expressed on nor-
mal and SS RBCs (26) and has been demonstrated to pro-
tect normal RBCs from immune clearance (27). More-
over, we previously demonstrated that under basal flow
conditions, IAP is a primary cell-surface adhesive mole-
cule on SS RBCs for immobilized TSP (26).
Although other hematopoietic cells become adhesive
in response to agonists or other stimuli, SS RBCs them-
selves are generally regarded to adhere passively to adhe-
sive sites in the vasculature. However, RBCs express a
number of agonist receptors including purinergic recep-
tors (28), a platelet-activating factor receptor (29), recep-
tors for IL-8 (30, 31), GPIV or CD36 (2, 32), and IAP (26).
While passive, basal SS RBC adhesion probably occurs
in SCD, the expression of agonist receptors on SS RBCs
suggests that SS RBC adhesion might also be regulated.
Given the elevated plasma levels of TSP in SCD patients
(20) and the signaling potential of these cells, we inves-
tigated a role for IAP in SS RBC activation. We demon-
strate that occupancy of IAP on the SS RBC activates a
shear stress–dependent, large G protein–mediated signal
transduction pathway that substantially promotes adhe-
sion of SS RBCs to immobilized TSP. We also provide
evidence that one or more piceatannol-sensitive tyrosine
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kinases becomes activated via a novel synergy between
IAP signaling and shear-stress, suggesting that tyrosine
kinase activation in the SS RBC is required for IAP-stim-
ulated adhesion under flow conditions. These results
therefore identify the SS RBC as a signal-transducing cell
and document a new paradigm for the regulation of SS
RBC adhesion in the vasculature.
Methods
Reagents. Human TSP-1 purified from platelets was
obtained from Life Technologies Inc. (Grand Island,
New York, USA), Calbiochem-Novabiochem Corp.
(La Jolla, California, USA), Sigma Chemical Co. (St.
Louis, Missouri, USA), or Cortex Biochemical (San
Leandro, California, USA), and also kindly provided
by Dean Mosher (University of Wisconsin at Madi-
son, Madison, Wisconsin, USA) and Jack Lawler
(Brigham and Women’s Hospital and Harvard Med-
ical School, both of Boston, Massachusetts, USA).
Antibodies against IAP, B6H12, and1F7, were gener-
ous gifts from Eric Brown (University of California-
San Francisco, San Francisco, California, USA). The
TGF-β neutralizing mAb was purchased from Chemi-
con International (Temecula, California, USA).
Recombinant TGF-β was purchased from Serotec
Inc. (Raleigh, North Carolina, USA). Initially, TSP
peptides 4N1K (kRFYVVMWKk) and control 4NGG
(kRFYGGMWKk) were provided by William Frazier
(Washington University, St. Louis, Missouri, USA)
(21). These peptides were also synthesized and HPLC-
purified by the University of North Carolina-Chapel
Hill Protein Chemistry Laboratory. Pertussis toxin,
piceatannol, and genistein were obtained from Cal-
biochem-Novabiochem Corp.
RBC preparation. SS RBCs were obtained from
homozygous SCD patients with informed consent
during clinic visits to the University of North Caroli-
na Comprehensive Sickle Cell Center or obtained
from healthy controls. All blood samples were drawn
by venipuncture into 0.13 M sodium citrate and
processed immediately by centrifugation at 150 g for
15 minutes at ambient temperature to isolate blood
cells from plasma and platelets. RBCs were then
washed three times in CGS (1.29 mM sodium citrate,
3.33 mM glucose, and 124 mM NaCl [pH = 7.2]). The
cells were resuspended in PBS and packed at 400 g for
10 minutes. A 1% hematocrit was then prepared by
diluting 30 µl of packed RBCs per 1.5 ml of perfusion
media (HBSS supplemented with 0.3% BSA and 20
mM HEPES [pH = 7.4]). This preparation essentially
removed all platelets from the washed RBCs (platelet
count < 250 per 3 × 108 RBCs) and eliminated most
white blood cells (WBCs), although WBC counts var-
ied between preparations. Frequently, we were unable
to detect WBCs in our samples by direct examination
of stained preparations. On average, less than 0.5% of
this preparation were WBCs in all experiments except
one, in which 1–2% WBCs were present. To confirm
that any WBC contamination did not compound our
experimental results, we evaluated the contribution of
WBCs at the maximal detected contaminating num-
bers (the 1–2% range) unless otherwise noted. 
WBC preparation. WBCs were prepared by layering
diluted buffy coats from separated whole blood over a
1.0770–1.0800 Ficoll-sodium diatrizoate solution. The
layers were then spun at 400 g for 25 minutes. WBCs
were collected, washed in PBS, and resuspended at
appropriate concentrations in perfusion media.
Flow adhesion assay and protein immobilization. The flow
adhesion system used for this study was designed to
mimic blood flow through postcapillary venules, as
described previously (5). Briefly, purified TSP (1.5 µg) in
perfusion media was immobilized onto identical wells
formed by a silicon gasket in a 35-mm polystyrene cul-
ture dish by incubating for 2 hours at 37°C. A 1% hema-
tocrit solution (1.5 ml) was flowed over the wells at a rate
of 1.0 ml/min and constant shear stress of 1 dyne/cm2.
After a wash period of approximately 4 minutes, the
number of adherent cells from four representative areas
of the well was counted by direct light microscopy. The
counted cells were then averaged and presented as adher-
ent cells per square millimeter. Any occasional adherent
WBC was not included in the analysis.
SS RBC static adhesion assay. The static adhesion assay
used for this study is based on an ATP monitoring sys-
tem, ATP-Lite (Packard, Groningen, The Nether-
lands). Microtiter plates (Becton Dickinson, Franklin
Lakes, New Jersey, USA) were coated with 1.5 µg TSP
for 2 hours at 37°C then blocked with 0.3% BSA for
30 minutes at 37°C. SS RBCs (3 × 106) or WBCs (6 ×
104) were added to each well and incubated for 2
hours at 37°C. Adherent cells were washed four times,
and remaining SS RBCs or WBCs were treated with
ATP-Lite for luminescence measurement in a
microtiter plate reader (TopCount; Packard Instru-
ment Co., Meriden, Connecticut, USA). Under these
conditions no platelet adhesion was observed. All
results were verified by direct counting of the SS RBCs
(positively identified by Wright/Giemsa staining) by
light microscopy (see Figure 3a) with the minimal
contaminating WBC ATP subtracted out.
RBC lysis and Western blotting. Cells were lysed for 20
minutes in ice-cold lysis buffer containing 1% Triton
X-100, 50 mM HEPES (pH 7.4), 137 mM NaCl, 500
µM EGTA, 100 mM NaVO3, 100 mM NaF, and 1X Pro-
tease Inhibitor Cocktail Set III (Calbiochem-Nov-
abiochem Corp.). The Triton X-100 soluble fraction
was incubated overnight at 4°C with either the anti-
phosphotyrosine antibody PY20 or PY99 (Santa Cruz
Biotechnology Inc., Santa Cruz, California, USA) at 2
µg/ml final concentration followed by incubation (1
hour) with protein G Sepharose beads. Immunopre-
cipitated proteins were washed three times in lysis
buffer, reduced according to the method of Laemmli
(33), loaded on 4–20% SDS-PAGE, transferred to
PVDF membrane (Millipore), and blotted with 4G10
anti-phosphotyrosine mAb (Transduction Laborato-
ries, Lexington, Kentucky, USA).
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Statistics. The significance of any differences for all
treatments studied was determined using a two-tailed
Student’s t test. Unless otherwise noted, P < 0.001.
Results
To evaluate the potential of SS RBCs to become more
adhesive in response to agonist-induced signaling, we
evaluated the ability of a known ligand and agonist for
IAP, soluble TSP, to promote SS RBC adhesion under
relevant flow conditions. Freshly drawn, washed human
SS RBCs were preincubated (30 minutes at 37°C) with
soluble TSP at concentrations reported to be present in
the plasma of SCD patients (20) (Figure 1a, inset) and
flowed over immobilized TSP under conditions that
mimics shear stress and flow in postcapillary venules
(5). Soluble TSP increased SS RBC adhesion to immo-
bilized TSP up to sixfold that of basal SS RBC adhesion
observed in the absence of soluble TSP (Figure 1a). This
activation of adhesion cannot be contributed to con-
taminating TGF-β that copurifies with TSP; we still
observed increased SS RBC adhesion in response to sol-
uble TSP that was preincubated with maximal concen-
trations of a neutralizing TGF-β mAb (data not shown).
Furthermore, purified, recombinant TGF-β had no
effect on SS RBC adhesion to TSP under flow condi-
tions (data not shown). These results indicate a poten-
tiating effect of soluble TSP on SS RBC adhesion to
immobilized TSP. Because of this promotion, rather
than inhibition, of SS RBC adhesion to immobilized
TSP by soluble TSP, it appears that soluble TSP binds
to SS RBCs by a mechanism distinct from that of
immobilized TSP, and potentially activates SS RBCs.
Because IAP is an agonist receptor in response to TSP
on other cells, we evaluated its role as an agonist receptor
for soluble TSP on SS RBCs with the IAP-function block-
ing mAb 1F7 (34). We found that TSP-stimulated adhe-
sion was completely blocked by 1F7 (1 µg/ml) (Figure 1c),
but not by an isotype-matched control antibody (data
not shown). These results suggest that IAP is essential for
the response to soluble TSP under these conditions.
To confirm that IAP occupancy can promote SS RBC
adhesion to immobilized TSP, we preincubated SS RBCs
with an IAP-specific agonist peptide derived from TSP,
termed 4N1K (21, 35). We had previously determined
that this peptide could support SS RBC adhesion under
flow conditions and that IAP under basal flow condi-
tions is an adhesion receptor on SS RBCs for TSP (26).
However, under identical shear conditions as above, the
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Figure 1
Soluble TSP or 4N1K agonist peptide promotes SS RBC adhesion to immobilized TSP via IAP. (a) Increasing concentrations of soluble TSP, includ-
ing those reported in plasma of SCD patients (20) (inset), cause increased SS RBC adhesion to immobilized TSP under flow (flow rate: 1 ml/min,
shear: 1 dyne/cm2). Data plotted represent results from six different patients ± SD. (b) Increasing concentrations of 4N1K agonist peptide
(kRFYVVMWKk) promote SS RBC adhesion to immobilized TSP (squares), whereas the 4NGG control peptide (kRFYGGMWKk) has no effect on
SS RBC adhesion to immobilized TSP under flow (triangles). Data were normalized from six independent patient samples and are shown as ± SD.
4N1K treatment has no effect on AA RBC adhesion (circles, n = 3 donors). (c) 4N1K (16 µM) and TSP-stimulated (50 nM) adhesion to immo-
bilized TSP can be blocked by a 20-minute pretreatment of SS RBCs with 1F7 (1 µg/ml) before agonist treatment (mean of n = 3 patients, ± SD).
soluble 4N1K peptide did not block adhesion, but max-
imally stimulated SS RBC adhesion to immobilized TSP
sevenfold (Figure 1b, squares), whereas a control peptide,
4NGG (21, 35), had little effect on SS RBC adhesion
(Figure 1b, triangles). This stimulatory effect of the
4N1K peptide on adhesion was also blocked by mAb 1F7
(1 µg/ml), thus indicating an IAP-specific interaction
with the agonist peptide (Figure 1c). This result suggests
that, in this context, IAP functions as an agonist, rather
than adhesion receptor, on SS RBCs. SS RBC adhesion
to immobilized TSP doubled after 2 minutes and was
maximal within 30 minutes of pretreatment with the
4N1K peptide (data not shown), suggesting a relatively
slow activation of adhesion. However, in contrast to SS
RBCs, treatment of AA RBCs with the 4N1K agonist
peptide did not stimulate adhesion to immobilized TSP
(Figure 1b, circles), suggesting that this adhesive pheno-
type may not be relevant to normal peripheral RBCs.
We next investigated the effects of another IAP-specif-
ic mAb, B6H12, on SS RBC adhesion to immobilized
TSP. B6H12 blocks ligand binding to IAP on most cells
(22, 34), but stimulates IAP signaling in at least one cell
type (23). We observed that B6H12 increased SS RBC
adhesion to immobilized TSP under shear conditions
(Figure 2a). This result further supports a role for IAP as
an agonist receptor on SS RBCs that activates adhesion.
To determine the contribution of shear stress to TSP
agonist-induced adhesion, we examined SS RBC adhe-
sion to immobilized TSP in the absence of shear. For
this purpose, a static adhesion assay was designed in a
96-well format. We found two immediate differences
between sickle cell adhesion under shear versus static
conditions. First, although B6H12 stimulated SS RBC
adhesion in the flow adhesion assay (Figure 2a), treat-
ment with this mAb, but not an isotype-matched con-
trol mAb, completely blocked SS RBC adhesion to TSP
in the static adhesion assay (Figure 2b). Second,
although the 4N1K agonist peptide stimulated sickle
cell adhesion to immobilized TSP under flow (Figure
1b), SS RBC treatment with the 4N1K peptide
(squares), but not the control 4NGG peptide (ovals),
completely inhibited sickle cell adhesion to immobi-
lized TSP in the static assay (Figure 2c). These results
suggest that under static conditions, IAP is a major
sickle cell adhesion receptor for immobilized TSP.
These data also suggest that shear stress provides an
essential component to the activation of SS RBC adhe-
sion that occurs in response to 4N1K, soluble TSP or
B6H12 binding to IAP on the SS RBC. Thus, although
IAP clearly appears to be a major static adhesion recep-
tor for immobilized TSP, our results also suggest that
IAP can function as an agonist receptor that, under rel-
evant flow conditions, potentially activates shear-
dependent signal transduction in the SS RBCs.
We next tested our hypothesis that IAP activates a sig-
naling pathway in SS RBCs that, under flow condi-
tions, promotes adhesion to immobilized TSP. In
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Figure 3
IAP-induced adhesion of SS RBCs requires Gi and tyrosine kinase activ-
ity. (a) SS RBC adhesion to immobilized TSP under flow conditions,
stimulated by a submaximal concentration of agonist peptide 4N1K
(16 µM), is completely blocked by pretreatment (30 minutes) with the
large G protein inhibitor pertussis toxin (1 µg/ml) or the tyrosine kinase
inhibitors genistein (260 µM) or piceatannol (30 µg/ml). (b) SS RBC
adhesion to immobilized TSP that is stimulated by a submaximal con-
centration of soluble TSP (2 nM) is partially blocked by preincubation
with pertussis toxin (1 µg/ml) and completely blocked with genistein.
Normalized data with basal adhesion subtracted out represent four
4N1K- and two TSP-treated patient samples, respectively (± SD).
Figure 2
IAP stimulation of SS RBC adhesion is shear-dependent. (a) Prein-
cubation (30 minutes) of SS RBCs with anti-IAP mAb B6H12 
(1 µg/ml) increases SS RBC adhesion under flow conditions (n = 5
patients, ± SD). (b) B6H12 (1 µg/ml) blocks SS RBC adhesion to
TSP under static conditions (n = 3 patients). Basal, nonstimulated
SS RBC adhesion is set at 100%. Identical treatment with an isotype-
matched control antibody (1 µg/ml) has no effect on adhesion under
flow (a) or static (b) conditions. (c) Agonist peptide 4N1K blocks SS
RBC adhesion to immobilized TSP under static conditions (squares),
whereas 4NGG control peptide (ovals) has little effect on static SS
RBC adhesion (n = 3 patients, ± SD).
platelets and smooth muscle cells, IAP functionally
couples to, and signals via, the large G protein Gi (22,
36). In addition, several nonreceptor tyrosine kinases
have been implicated in IAP signaling (22, 23). To
examine potential IAP signaling in SS RBCs, we pre-
treated SS RBCs with the Gi inhibitor pertussis toxin (1
µg/ml, 30 minutes) and stimulated the cells with the
4N1K agonist peptide. Pertussis toxin treatment
almost completely blocked the 4N1K-stimulated com-
ponent of SS RBC adhesion to immobilized TSP (Fig-
ure 3a), but had no effect on basal, nonagonist-stimu-
lated adhesion to TSP (data not shown), suggesting a
role for Gi activation downstream of IAP in SS RBCs.
Pertussis toxin also blocked soluble TSP-stimulated
adhesion to immobilized TSP, but by about 50% (Fig-
ure 3b), suggesting that soluble TSP may act via multi-
ple signaling pathways in the SS RBCs (Figure 3b).
Consistent with a role for tyrosine kinase activity in IAP
signaling, the tyrosine kinase inhibitor piceatannol (30
µg/ml) also blocked 4N1K-stimulated SS RBC adhe-
sion to immobilized TSP under flow conditions. Treat-
ment with genistein (260 µM), another tyrosine kinase
inhibitor, also partially blocked the SS RBC response
to the 4N1K peptide (Figure 3a), but completely
blocked the response to soluble TSP (Figure 3b), fur-
ther implying that tyrosine kinase become activated as
a result of 4N1K or TSP stimulation. Neither inhibitor
had any effect on basal SS RBC adhesion (data not
shown). These results indicate that 4N1K-induced IAP
signaling in SS RBCs is similar to that in other agonist-
regulated cells and involves the activation of large G
proteins and tyrosine kinases.
Another potent inducer of intracellular signaling in
several cell types is the shear stress that results from
exposure of cells to blood flow. Endothelial cells
exposed to shear exhibit marked differences in receptor
expression, differentiation, and cell signaling (37, 38).
Likewise, platelets exposed to high shear arterial blood
flow can spontaneously activate (39) and adhere to the
blood vessel wall by mechanisms distinct from platelets
under slower venous flow conditions (40, 41).
To explore further the shear-induced component of
IAP signaling in SS RBCs, we exposed nonstimulated SS
RBCs to a 2-minute pulse of shear identical to that pres-
ent in the flow adhesion assay. The cells were lysed
immediately after shear and were analyzed by immuno-
precipitation of tyrosine-phosphorylated proteins fol-
lowed by SDS-PAGE and immunoblotting. As shown in
a representative blot (Figure 4a), exposure of SS RBCs
to shear alone induced both the phosphorylation and
dephosphorylation of several protein bands relative to
SS RBCs under static conditions. Most notably, pro-
teins migrating at approximately 100 and 70 kDa
became markedly phosphorylated, whereas proteins
migrating at approximately 45 and 27 kDa lost phos-
photyrosine content. These results show that both
shear-dependent tyrosine phosphorylation and dephos-
phorylation of proteins occur in the SS RBCs and fur-
ther support a role for shear stress in the activation of
SS RBC adhesion. To investigate the combined effects
of IAP-mediated signaling and shear on cellular protein
phospho-tyrosine content, we stimulated SS RBCs with
the 4N1K agonist peptide (100 µM), exposed the cells to
shear stress, and analyzed phosphotyrosine content as
above. The combination of agonist peptide and shear
stress further increased the tyrosine phosphorylation of
the 100- and 70-kDa bands and caused the appearance
of several additional bands (Figure 4b, lane 3). This
increase in tyrosine phosphorylation of the 100- and 70-
kDa bands was completely blocked by pretreatment of
SS RBCs with piceatannol (Figure 4c, lane 2). Examina-
tion of the phosphotyrosine content of an overestimate
of contaminating numbers of purified WBCs (200,000
cells) or platelets (50,000) under identical treatment
conditions indicated a lack of detectable tyrosine phos-
phorylation in these cells, even under shear stress cou-
pled with 4N1K stimulation (Figure 4b, lanes 1 and 2).
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Figure 4
Shear stress and IAP stimulation induce tyrosine phosphorylation
and dephosphorylation in SS RBCs. (a) SS RBCs (1 × 107) were lysed
after 2 minutes of shear stress alone (1 dyne/cm2), and tyrosine
phosphorylated proteins were immunoprecipitated with PY20 (lanes
2 and 5), PY99 (lanes 1 and 4), or control IgG (lane 3) and Western
blotted with 4G10. Exposure to shear induces the phosphorylation
of several bands at ~100 kDa and 70 kDa (arrows). Notable dephos-
phorylation occurs at approximately 45, 30, and 27 kDa (represen-
tative of three patients). (b) 4N1K (100 µM) plus shear induces the
further phosphorylation at 100 kDa and 70 kDa relative to 4NGG
plus shear (lane 5). Control IgG fails to detect this phosphorylation
(lane 4). NeitherWBCs (200,000, lane 1) nor platelets (50,000, lane
2) exhibit any change in phosphorylation (blot representative of four
patients). (c) Pretreatment with piceatannol (lane 2) blocks tyrosine
phosphorylation of the 100- and 70-kDa bands induced by shear
plus 4N1K treatment (lane 1, top arrows) back to control peptide
levels (lane 3) (blot representative of two patients). Piceatannol
potentiated the 4N1K-induced phosphorylation of a 33-kDa band
(lane 2, lower arrow). (d) Normal (AA) RBCs do not exhibit any
change in tyrosine phosphorylation in response to 4N1K and shear
stimulation (blot representative of four donors and exposed eight
times longer than SS blots) using either PY99 (lanes 1 and 4), PY20
(lanes 2 and 5), or control IgG (lane 3). Note the lack of phospho-
rylated bands at 100 kDa and 70 kDa (arrows).
These data indicate that the change in protein tyrosine
phosphorylation from both shear stress and 4N1K pep-
tide stimulation occurs in the SS RBCs. Furthermore,
treatment of SS RBCs with piceatannol blocked 4N1K-
induced tyrosine phosphorylation (Figure 4c, lane 2),
consistent with this inhibitor’s ability to block IAP-
stimulated adhesion. These results demonstrate that
the SS RBC is initiating cell signaling in response to
changes in its environment that can result in increased
adhesion of these cells.
Interestingly, the 4N1K peptide can induce moder-
ate tyrosine phosphorylation of the 100- and 70-kDa
bands in the absence of shear (data not shown). Fur-
thermore, immobilized TSP also induces tyrosine
phosphorylation of these protein bands under static
conditions (data not shown). Yet, the presence of
either agonist alone fails to activate SS RBC adhesion
in the absence of shear. These results further indicate
that full IAP stimulation of SS RBC adhesion
absolutely requires a novel synergy between shear
stress and receptor ligation. Additionally, AA RBCs,
which failed to functionally respond to agonist pep-
tide stimulation (Figure 1b), also exhibited almost no
change in amounts of tyrosine phosphorylated pro-
teins under any of the tested conditions (Figure 4d),
again suggesting an SS RBC-specific response to IAP
stimulation and shear.
Given that reticulocytes may retain several signaling
pathways and molecules that are lost upon normal RBC
maturation (42), we hypothesized that it was these
young RBCs that were mounting the signaling response
to IAP. Therefore, we separated SS RBCs on an arabino-
galactan gradient (26) and tested the ability of the low-
density (reticulocyte-enriched) and high-density (retic-
ulocyte-depleted) fractions to respond to 4N1K
stimulation under flow conditions. The low-density
fraction exhibited a robust response to the 4N1K but
not the 4NGG peptide, whereas the reticulocyte-deplet-
ed fraction was markedly deficient in response to 4N1K
stimulation of adhesion in two separate patients (Fig-
ure 5a). These results strongly suggest that the low-den-
sity, reticulocyte-enriched fraction of SS RBCs repre-
sents the most reactive population of SS RBCs.
Moreover, RBCs from a patient with an idiopathic
hemolytic anemia and markedly elevated reticulocyte
count (35–40%), but AA hemoglobin, clearly responded
to 4N1K agonist peptide or soluble TSP stimulation
under flow (Figure 5b), suggesting that an increased
reticulocyte population is sufficient to confer a
response to IAP stimulation. Interestingly, this patient’s
RBCs, unlike SS RBCs, failed to adhere basally to immo-
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Figure 6
Model of SS RBC activation by plasma TSP and shear stress. We pre-
viously demonstrated that basal or resting SS RBCs (left) could adhere
to immobilized TSP (representing subendothelial matrix- or cell-asso-
ciated TSP in vivo) by an IAP-mediated adhesion to the “cell binding
domain” of TSP (binding site 1) when soluble TSP levels are negligi-
ble, as in individuals who do not have SCD. In contrast, when plasma
levels of TSP are elevated, as in SCD, we propose that IAP is largely
occupied by plasma TSP and unable to participate directly in adhe-
sion to immobilized TSP. However, IAP stimulation by plasma TSP in
combination with physiological shear stress, via a Gi- and tyrosine
kinase–dependent pathway, activates a distinct, yet unidentified, TSP
receptor that preferentially recognizes immobilized matrix- or cell-
associated TSP (binding site 2). We further propose that site 2 is rel-
atively inaccessible in plasma TSP, thus explaining the marked IAP-
mediated activation of SS RBCs by soluble TSP, instead of an
inhibition of adhesion to immobilized TSP. Finally, we demonstrate
that activation of a distinct TSP receptor more than compensates for
a loss of direct IAP adhesion to immobilized TSP, therefore promot-
ing overall SS RBC avidity for immobilized TSP.
Figure 5
The low-density (reticulocyte-enriched) fraction of SS RBCs is most
responsive to IAP stimulation. (a) Reticulocyte-enriched fractions of SS
RBCs from two patients were prepared by centrifuging washed SS RBC
over an arabinogalactan gradient (Larex Inc., White Bear Lake, New
Jersey, USA) (74,000 g, 20°C, 45 minutes). SS RBCs collected from
low- and high-density fractions were resuspended in perfusion media
and packed at 400 g. A 1% hematocrit of each fraction was prepared,
treated with or without 50 µM 4N1K peptide, and flowed over immo-
bilized TSP. (b) AA reticulocytes respond to 4N1K stimulation. Washed
RBCs from a patient with a hemolytic anemia and increased reticulo-
cyte count were treated with 50 µM 4N1K agonist, 50 µM control
4NGG peptide, or 2 nM soluble TSP and flowed over immobilized TSP.
Data are presented ± SD (n = 2 experiments) and are expressed in both
panels as adherent cells per square millimeter.
bilized TSP under flow conditions (J.E. Brittain and L.V.
Parise, unpublished observations), which might be
explained by a physical difference in IAP that we previ-
ously noted on SS RBCs (26). These results further sug-
gest that the more immature RBCs in SCD, and perhaps
other anemias, respond to agonist stimulation.
Discussion
In summary, we show an unprecedented role for IAP-
mediated signaling in sickle erythrocytes and demon-
strate a new potential pathological role for this recep-
tor in SCD. We find that in the presence of shear stress,
IAP specifically activates SS RBC adhesion to immobi-
lized TSP via a Gi, and tyrosine kinase-dependent path-
way. Our data suggest that this synergy between IAP
and shear leads to the activation of as yet uncharacter-
ized TSP receptors on SS RBCs that preferentially bind
to immobilized, or matrix TSP, in the presence of solu-
ble TSP or the 4N1K agonist peptide (43).
In a previous study, we identified IAP as a TSP recep-
tor on SS RBCs that mediates a significant amount of
the basal adhesion of these cells to immobilized platelet
TSPs under relevant flow conditions (26). As illustrated
in a model (Figure 6), our data also suggest that with
elevated plasma TSP as in SCD, IAP is largely occupied
by soluble TSP, which activates a distinct TSP recep-
tor(s) that efficiently binds to an adhesive, exposed site
on TSP (binding site 2) when TSP is constrained on a
solid-phase support. We predict that such conforma-
tions of TSP would be presented to SS RBCs in flowing
blood either as exposed matrix TSP or as plasma TSP
bound to the endothelium. The dependence of TSP-
induced signaling on shear stress further suggests that
the resulting adhesiveness of SS RBCs may be most rel-
evant in the initiation of vaso-occlusion in flowing
blood, which would serve to compromise blood flow,
induce turbulence, and slow transit through the vascu-
lature. In contrast, under largely static conditions,
which would be expected behind a vaso-occlusion, our
results suggest that IAP may function largely as an
adhesion receptor for TSP bound to various sites in the
vasculature, ultimately propagating vaso-occlusion.
Therefore, we believe that IAP is a viable, twofold thera-
peutic target whose disruption could decrease the fre-
quency and duration of vaso-occlusion in SCD.
It is intriguing that while SS RBCs respond to shear and
IAP signaling in SCD, normal peripheral RBCs, which
express IAP and are constitutively exposed to shear in
vivo, remain nonresponsive under any of our studied con-
ditions. The rapid clearance of SS RBCs leads to an
increased reticulocyte population and younger average
age of all circulating RBCs in SCD patients. Our data sug-
gest that these young peripheral cells retain signaling
molecules and pathways lost in more mature RBCs and,
as a result, are the most responsive to IAP-induced SS
RBC signaling. In fact, peripheral reticulocytes are rare in
normal peripheral blood, and the minimal numbers of
these cells in normal donors could account for the lack of
response of normal patients. Therefore, our data also sug-
gest that several pathological anemias may render
patients vulnerable to increased reticulocyte adhesion as
a result of signal transduction in the cells.
We propose that SCD patients would be particularly
vulnerable to TSP-stimulated RBC adhesion, due to
both elevated plasma levels of TSP and increased retic-
ulocyte counts (1, 20). Under shear conditions, soluble
TSP, present presumably in multiple conformations in
the plasma of SCD patients, could induce IAP-activat-
ed sickle cell adhesion to TSP bound to endothelial
cells or exposed in the subendothelial matrix in vivo,
dramatically promoting vaso-occlusion. In fact, a study
by Kumar et al. in which α4β1-mediated SS RBC adhe-
sion to endothelial cells appeared to be upregulated by
IL-8 or PMA (44), is consistent with our results that sig-
nal transduction in SS RBCs can be a basis for increas-
ing sickle cell adhesion. Our data demonstrate, howev-
er, that IAP-mediated signaling in combination with
shear-stress increases adhesiveness of SS RBCs, thus
providing a new paradigm of sickle cell adhesion.
Our data thus far suggest that SS RBCs may be capa-
ble of activating multiple signaling pathways, as 4N1K-
and TSP-stimulated pathways are affected in a similar
but not identical manner to signaling inhibitors. SS
RBCs express at least one additional TSP receptor, GPIV
or CD36, a known signaling receptor on other cells that
may affect the TSP- but not 4N1K-induced SS RBC sig-
naling. Also, the points at which shear and IAP signal-
ing impinge in SS RBCs, and the identity of the IAP-
activated TSP receptor on SS RBCs, are unknown but
currently under investigation. Identification of each of
the signaling pathways stimulated by IAP, shear and/or
soluble TSP increases the likelihood that additional
therapeutic targets will be identified to downregulate
SS RBC adhesion and vaso-occlusive crises in SCD.
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